Actively Recruiting
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
Led by Takeda · Updated on 2025-12-24
257
Participants Needed
1
Research Sites
363 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of brigatinib among adult participants who have been administered brigatinib as per the approved indications.
CONDITIONS
Official Title
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of ALK-positive advanced or metastatic non-small-cell lung cancer
- Starting brigatinib treatment for the first time
You will not qualify if you...
- Treatment with brigatinib outside the locally approved label in Korea
- Contraindications to brigatinib as per product label
- Participation in other clinical trials for non-small-cell lung cancer treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pusan National University Hospital
Busan, South Korea, 49241
Actively Recruiting
Research Team
T
Takeda Contact
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here